March 15, 2016

Basilea issues agenda for Annual General Meeting of Shareholders




  • Dr. Martin Nicklasson has determined not to stand for re-election as Chairman but will stand for re-election as Member of the Board
  • Domenico Scala nominated as new Chairman of the Board

Basel, Switzerland, March 15, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) issued on its company website today the agenda for its 2016 Annual General Meeting of Shareholders (AGM) which will be held on April 21, 2016 in Basel. The full invitation including the agenda will be published in the Swiss Official Gazette of Commerce in due course.

The Chairman of the Board, Dr. Martin Nicklasson, has informed the board that he will not stand for re-election as Chairman at the 2016 AGM. Dr. Nicklasson will stand for re-election as a board member. Dr. Nicklasson has been Chairman of the Board since 2013. During his tenure, Basilea successfully gained regulatory approval for and launched CRESEMBA® and Zevtera®. The board thanks Dr. Nicklasson for his contributions as Chairman.

The board proposes that the shareholders elect Domenico Scala as the new Chairman of the Board. Mr. Scala, a Swiss and Italian citizen, has served as a Member of Basilea's Board of Directors and its Vice-Chairman since 2011. From 2007 to 2011, he was President and Chief Executive Officer of Nobel Biocare Holding AG and from 2003 to 2007, he was Chief Financial Officer of Syngenta International AG. From 1995 to 2003, Mr. Scala served in various senior leadership positions at Roche Holding AG. Mr. Scala is Chairman of the Audit and Compliance Committee of FIFA (Fédération Internationale de Football Association) and President of BaselArea. He graduated from the University of Basel with a degree in economics and holds Executive Development degrees from INSEAD and London Business School.

According to Basilea's current Organizational Regulations, the term of each member of the Board of Directors ends effective as per the AGM immediately following completion of his or her 70th year of age. For this reason, Mr. Hans-Beat Gürtler, board member since 2009, will not stand for re-election at the 2016 AGM. The board thanks Mr. Gürtler for his commitment to Basilea and his service on the board. The remaining current board members will stand for re-election at the AGM: Prof. Daniel Lew, Dr. Martin Nicklasson, Dr. Thomas M. Rinderknecht, Mr. Domenico Scala, Mr. Steven Skolsky, and Dr. Thomas Werner.

The full agenda can be viewed on the company website. Printed invitations will be sent by post to shareholders, and those shareholders and usufructuaries who as per April 8, 2016 are recorded in the share register with voting rights are entitled to participate and exercise their voting rights at the AGM.

About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD
Head Public Relations & Corporate Communications
+41 61 606 1102

This press release can be downloaded from